Project Title

A study of Pirtobrutinib (LOXO-305) versus Ibrutinib in participants with chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL)

Official Title

A Phase 3 open-label, randomized study of Pirtobrutinib (LOXO-305) versus Ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (BRUIN-CLL-314)

Project Summary

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.

Blood Disorder

• Chronic Lymphocytic Leukaemia/Small Lymphocytic Leukaemia

Patient Recruitment Details

Patient recruitment status: open

Number of patients (Globally)

650